[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367627-105":59,"doc-detail-367627-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pharmacologic-inhibition-of-bmi1-exerts-antitumor-effects-against-mycn-amplified-neuroblastoma-with-activation-of-the-p53-pathway","Pharmacologic inhibition of BMI1 exerts antitumor effects against MYCN-amplified neuroblastoma - with activation of the p53 pathway","","Pharmacologic inhibition of BMI1 was evaluated using the BMI1 inhibitors PTC-028 and PTC-209 to test antitumor activity against MYCN-amplified neuroblastoma. PTC-028 induced apoptosis, caused G1-phase cell-cycle arrest, reduced S-phase and G2/M populations, and activated the p53 signaling pathway. Treatment lowered anti-apoptotic proteins including BCL2 and MCL1 and demonstrated antitumor efficacy in a human neuroblastoma mouse xenograft model, supporting BMI1 inhibition as a therapeutic strategy for aggressive MYCN-driven disease.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pharmacologic-inhibition-of-bmi1-exerts-antitumor-effects-against-mycn-amplified-neuroblastoma-with-activation-of-the-p53-pathway/367627/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pharmacologic-inhibition-of-bmi1-exerts-antitumor-effects-against-mycn-amplified-neuroblastoma-with-activation-of-the-p53-pathway/367627.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which BMI1 inhibitors were tested against MYCN-amplified neuroblastoma?","Question",{"text":112,"@type":113},"PTC-028 and PTC-209 were evaluated for selective antitumor activity against MYCN-amplified neuroblastoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does PTC-028 affect neuroblastoma cells at the cellular level?",{"text":117,"@type":113},"PTC-028 triggered apoptosis and promoted cell-cycle arrest by inducing G1-phase accumulation while reducing S-phase and G2/M-phase populations.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links PTC-028 treatment to apoptosis induction?",{"text":121,"@type":113},"RNA sequencing indicated that PTC-028 activates the p53 signaling pathway, alongside reductions in anti-apoptotic proteins such as BCL2 and MCL1.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367627,1790900090,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPharmacologic inhibition of BMI1 exerts antitumor effects against MYCN-amplified neuroblastoma, with activation of the p53 pathway  \nMasahiro Hirayama1, Eri Yamada1, Hiromasa Aoki1, Kazuya Izumi1, Ayumi Amano1, Kohki Toriuchi1, Koichi Ogami2, Mai Nagasaka3, Yasumichi Inoue3, Hidetoshi Hayashi3, Satoru Takeshita1,4, Hiroki Kakita1,4, Yasumasa Yamada4 & Mineyoshi Aoyama1􀀍  \nBMI1, a constituent of polycomb repressive complex 1, is overexpressed in a variety of cancers, including neuroblastoma, highlighting its potential as a target for cancer therapeutics. Given the pivotal role of BMI1, a number of inhibitors have been synthesized and assessed for therapeutic efficacy across a spectrum of cancers. In our present study, the BMI1 inhibitors PTC-028 and PTC-209 exhibited selective antitumor activity against MYCN-amplified neuroblastoma. Notably, PTC-028, which exhibited toxicity at lower concentrations, triggered apoptosis in neuroblastoma cells and induced G1-phase accumulation, along with reductions in S-phase and G2/M-phase populations, thereby promoting cell cycle arrest. Thorough RNA sequencing analyses revealed that PTC-028 treatment activated the p53 signaling pathway, suggesting it plays a critical role in the mechanism of apoptosis induction. Moreover, PTC-028 treatment led to decreases in levels of anti-apoptotic proteins, including BCL2 and MCL1. Significantly, PTC-028 also exhibited antitumor efficacy in a mouse xenograft model of human neuroblastoma. These results suggest that BMI1 inhibitors, particularly PTC-028, are promising therapeutic agents for the management of aggressive MYCN-amplified neuroblastomas.  \nKeywords BMI1, Neuroblastoma, MYCN, p53, PTC-028  \nNeuroblastoma is one of the most common malignant tumors occurring in childhood, accounting for approximately 8% of all pediatric cancers1. Neuroblastoma tumors are thought to originate in the embryonal neural crest, with tumors primarily identified in the adrenal glands and sympathetic ganglia2,3. In addition, neuroblastoma exhibits a diverse range of clinical behaviors, from spontaneous regression to progression despite intensive treatments such as surgery, chemotherapy, and radiotherapy2,4. To guide prognosis and treatment strategies, patients with neuroblastoma are classified according to the International Neuroblastoma Risk Group staging system. This system incorporates tumor extent (including metastatic status), imaging-defined risk factors, patient age, and metastatic distribution to assign tumors to one of four pre-treatment stages: L1, L2, M, or MS. The staging classification, along with genomic features such as MYCN amplification, 11q deletion, and ploidy, are integrated to categorize patients into very-low-risk, low-risk, intermediate-risk, or high-risk groups2. The current 5-year overall survival rate for children diagnosed with advanced-stage neuroblastoma is \u003C 50%5, underscoring the urgent need for new therapeutic strategies.  \nMYCN amplification is strongly associated with tumor progression and poor clinical outcomes in neuroblastoma. Importantly, it serves as an independent prognostic factor, regardless of disease stage or age at diagnosis, and it is used as a key biomarker in neuroblastoma risk stratification2. Amplification of the MYCN gene is observed in approximately 20% of all neuroblastomas and 50% of high-risk cases, and it is a key biomarker of poor prognosis1,2,6. MYCN, a member of the MYCfamily that also includes C-MYC andL-MYC, is predominantly  \n1Department of Pathobiology, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabedori, Mizuho-ku, Nagoya 467-8603, Japan. 2Division of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.  \n3Department of Cell Signaling, Nagoya City University Graduate School of Pharmaceutical Scie","cbCaia9HfJ3aQYK0","https://ap.wps.com/l/cbCaia9HfJ3aQYK0","pdf",6421112,15,"English","# Background\n## Neuroblastoma risk stratification and prognosis\n## MYCN amplification and its clinical relevance\n## Role of MYCN in transcriptional regulation\n## BMI1 and PRC1-mediated epigenetic control\n# Study findings\n## Selective antitumor activity of PTC-028 and PTC-209\n## PTC-028–induced apoptosis and cell-cycle arrest\n## Activation of the p53 pathway and changes in apoptosis regulators\n## In vivo efficacy in a xenograft model","[{\"question\":\"Which BMI1 inhibitors were tested against MYCN-amplified neuroblastoma?\",\"answer\":\"PTC-028 and PTC-209 were evaluated for selective antitumor activity against MYCN-amplified neuroblastoma.\"},{\"question\":\"How does PTC-028 affect neuroblastoma cells at the cellular level?\",\"answer\":\"PTC-028 triggered apoptosis and promoted cell-cycle arrest by inducing G1-phase accumulation while reducing S-phase and G2/M-phase populations.\"},{\"question\":\"What mechanism links PTC-028 treatment to apoptosis induction?\",\"answer\":\"RNA sequencing indicated that PTC-028 activates the p53 signaling pathway, alongside reductions in anti-apoptotic proteins such as BCL2 and MCL1.\"}]","Pharmacologic inhibition of BMI1 exerts antitumor effects against MYCN-amplified neuroblastoma - with activation of the p53 pathway | PDF",1790171676,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/510eb234723b30a363b9390bd8f2bc33.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4f206afe6d9fbc8655e54393f3d3e3f.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/afe658d50af67320946e95c73227a1a6.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edcc23a5251904b58b63361da81d1dbc.webp",980,1287]